A. Abbasi, L. M. Kieneker, E. Corpeleijn, R. T. Gansevoort, R. O. Gans et al., Plasma N-terminal prosomatostatin and risk of incident cardiovascular disease and all-cause mortality in a prospective observational cohort: the PREVEND study, Clin. Chem, vol.63, pp.278-287, 2017.

M. Albert, Y. Zhu, A. Moghekar, S. Mori, M. I. Miller et al., Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years, Brain, vol.141, pp.877-887, 2018.

M. S. Albuquerque, I. Mahar, M. A. Davoli, J. Chabot, N. Mechawar et al., Regional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer's disease. Front, Aging Neurosci, vol.7, p.30, 2015.

N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele et al., Evaluation of CSF-tau and CSF-A?42 as diagnostic markers for Alzheimer disease in clinical practice, Arch. Neurol, vol.58, pp.373-379, 2001.

C. Aoki and V. M. Pickel, Neuropeptide Y in the cerebral cortex and the caudate-putamen nuclei: ultrastructural basis for interactions with GABAergic and non-GABAergic neurons, J. Neurosci, vol.9, pp.4333-4354, 1989.

J. R. Atack, M. F. Beal, C. May, J. A. Kaye, M. F. Mazurek et al., Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs, Arch. Neurol, vol.45, pp.269-274, 1988.

R. J. Bateman, C. Xiong, T. L. Benzinger, A. M. Fagan, A. Goate et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med, vol.367, pp.795-804, 2012.

E. Borbély, B. Scheich, and Z. Helyes, Neuropeptides in learning and memory, Neuropeptides, vol.47, pp.439-450, 2013.

V. Chan-palay, Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons and effects in Alzheimer-type dementia, J. Comp. Neurol, vol.260, pp.201-223, 1987.

M. Chupin, A. Hammers, R. S. Liu, O. Colliot, J. Burdett et al., Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation, Neuroimage, vol.46, pp.749-761, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00805390

S. Craft, S. Asthana, J. W. Newcomer, C. W. Wilkinson, I. T. Matos et al., Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose, Arch. Gen. Psychiatry, vol.56, pp.1135-1140, 1999.

P. Davies, R. Katzman, and R. D. Terry, Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa, Nature, vol.288, pp.279-280, 1980.

D. A. De-luis, O. Izaola, B. De-la-fuente, D. Primo, A. et al., Association of neuropeptide Y gene rs16147 polymorphism with cardiovascular risk factors, adipokines, and metabolic syndrome in patients with obesity, J. Nutrigenet. Nutrigenomics, vol.9, pp.213-221, 2016.

L. C. De-souza, F. Lamari, S. Belliard, C. Jardel, C. Houillier et al., Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias, J. Neurol. Neurosurg. Psychiatry, vol.82, pp.240-246, 2011.

M. Del-campo, B. Mollenhauer, A. Bertolotto, S. Engelborghs, H. Hampel et al., Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update, Biomark. Med, vol.6, pp.419-430, 2012.

G. Deloche and D. Hannequin, DO 80 Epreuve de Dénomination Orale d'images, 1997.

M. Diez, S. Danner, P. Frey, B. Sommer, M. Staufenbiel et al., Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing ?-amyloid precursor protein (APP) with the Swedish double mutation (APP23), Neurobiol. Dis, vol.14, pp.579-594, 2003.

M. Diez, J. Koistinaho, K. Kahn, D. Games, and T. Hökfelt, Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F ?-amyloid precursor protein-initial observations, Neuroscience, vol.100, pp.259-286, 2000.

J. Duarte-neves, L. Pereira-de-almeida, and C. Cavadas, Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases, Neurobiol. Dis, vol.95, pp.210-224, 2016.

B. Dubois, H. H. Feldman, C. Jacova, H. Hampel, J. L. Molinuevo et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, issue.14, pp.70090-70090, 2014.

E. Duron and O. Hanon, Vascular risk factors, cognitive decline, and dementia. Vasc. Health Risk Manag, vol.4, pp.363-381, 2008.

L. Edvinsson, L. Minthon, R. Ekman, and L. Gustafson, Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration, Dementia, vol.4, pp.167-171, 1993.

S. Epelbaum, R. Genthon, E. Cavedo, M. O. Habert, F. Lamari et al., Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept, Alzheimers Dement, vol.13, pp.454-467, 2017.

J. Epelbaum, J. Guillou, F. Gastambide, D. Hoyer, E. Duron et al., Somatostatin, Alzheimer's disease and cognition: an old story coming of age?, Prog. Neurobiol, vol.89, pp.153-161, 2009.

J. Epelbaum, M. Ruberg, E. Moyse, F. Javoy-agid, B. Dubois et al., Somatostatin and dementia in Parkinson's disease, Brain Res, vol.278, issue.83, pp.90277-90286, 1983.

L. French, T. Ma, H. Oh, G. C. Tseng, and E. Sibille, Age-related gene expression in the frontal cortex suggests synaptic function changes in specific inhibitory neuron subtypes, Front. Aging Neurosci, vol.9, p.162, 2017.

A. Gabelle, J. Dumurgier, O. Vercruysse, C. Paquet, S. Bombois et al., Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM study, J. Alzheimers Dis, vol.34, pp.297-305, 2013.

S. M. Gabriel, L. M. Bierer, V. Harotunian, D. P. Purohit, D. P. Perl et al., Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex, Neurosci. Lett, vol.155, issue.93, p.90686, 1993.

M. D. Gahete, A. Rubio, M. Durán-prado, J. Avila, R. M. Luque et al., Expression of Somatostatin, cortistatin and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients, J. Alzheimers Dis, vol.20, pp.465-475, 2010.

P. Gaspar, C. Duyckaerts, A. Febvret, R. Benoit, B. Beck et al., Subpopulations of somatostatin 28-immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type, Brain Res, vol.490, pp.1-13, 1989.

E. Grober, H. Buschke, H. Crystal, S. Bang, and R. Dresner, Screening for dementia by memory testing, Neurology, vol.38, pp.900-903, 1988.

E. Grober, R. B. Lipton, C. Hall, C. , and H. , Memory impairment on free and cued selective reminding predicts dementia, Neurology, vol.54, pp.827-832, 2000.

D. Grouselle, R. Winsky-sommerer, J. P. David, A. Delacourte, P. Dournaud et al., Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele, Neurosci. Lett, vol.255, pp.21-24, 1998.

R. L. Handels, S. J. Vos, M. G. Kramberger, V. Jelic, K. Blennow et al., Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers, Alzheimers Dement, vol.13, pp.903-912, 2017.

O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-234, 2006.

T. Hedback, P. Almgren, P. M. Nilsson, and O. Melander, N-terminal prosomatostatin as a risk marker for cardiovascular disease and diabetes in a general population, J. Clin. Endocrinol. Metab, vol.101, pp.2016-1736, 2016.

M. Heilig, M. Sjögren, K. Blennow, R. Ekman, and A. Wallin, Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia, Biol. Psychiatry, vol.38, pp.210-216, 1995.

H. Holm, K. Nägga, E. D. Nilsson, F. Ricci, E. Cinosi et al., , 2017.

, N-terminal prosomatostatin and risk of vascular dementia, Cerebrovasc. Dis, vol.44, pp.259-265

S. Katz, A. B. Ford, R. W. Moscowitz, B. A. Jackson, and M. W. Jaffe, Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function, JAMA, vol.185, pp.914-919, 1963.

H. Kolsch, D. Lutjohann, F. Jessen, H. Urbach, K. Von-bergmann et al., Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease, J. Neural Transm, vol.113, pp.231-238, 2006.

N. W. Kowall and M. F. Beal, Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease, Ann. Neurol, vol.23, pp.105-114, 1988.

M. P. Lawton and E. M. Brody, Assessment of older people: self-maintaining and instrumental activities of daily living, Gerontologist, vol.9, pp.179-186, 1969.

S. Lehmann, J. Dumurgier, S. Schraen, D. Wallon, F. Blanc et al., A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles, Alzheimers Res. Ther, vol.6, p.38, 2014.

P. A. Low and W. Singer, Management of neurogenic orthostatic hypotension: an update, Lancet Neurol, vol.7, pp.70088-70095, 2008.

J. C. Martel, R. Alagar, Y. Robitaille, and R. Quirion, Neuropeptide Y receptor binding sites in human brain. Possible alteration in Alzheimer's disease, Brain Res, vol.519, pp.228-235, 1990.

G. Martel, P. Dutar, J. Epelbaum, and C. Viollet, Somatostatinergic systems: an update on brain functions in normal and pathological aging, Front. Endocrinol, vol.3, p.154, 2012.

E. Martignoni, F. Blandini, F. Petraglia, C. Pacchetti, G. Bono et al., Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type, J. Neural Transm. Park Dis. Dement. Sect, vol.4, pp.191-205, 1992.

A. D. Mccarthy, I. J. Owens, A. T. Bansal, S. M. Mctighe, T. J. Bussey et al., FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease, Pharmacol. Biochem. Behav, vol.98, pp.76-80, 2011.

E. R. Mcgrath, A. S. Beiser, C. Decarli, K. L. Plourde, R. S. Vasan et al., Blood pressure from mid-to late life and risk of incident dementia, Neurology, vol.89, pp.2447-2454, 2017.

G. Operto, M. Chupin, B. Batrancourt, M. Habert, O. Colliot et al., CATI: a large distributed infrastructure for the neuroimaging of cohorts, Neuroinformatics, vol.14, pp.253-264, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01303094

J. J. Palop and L. Mucke, Network abnormalities and interneuron dysfunction in Alzheimer disease, Nat. Rev. Neurosci, vol.17, pp.777-792, 2016.

R. C. Petersen, Mild cognitive impairment as a diagnostic entity, J. Intern. Med, vol.256, pp.183-194, 2004.

N. Philippi, V. Noblet, E. Duron, B. Cretin, C. Boully et al., Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairment, Alzheimers Res. Ther, vol.8, p.26, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01382516

F. Portet, P. J. Ousset, P. J. Visser, G. B. Frisoni, F. Nobili et al., Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, vol.77, pp.714-718, 2006.

B. Ramos, D. Baglietto-vargas, J. C. Del-rio, I. Moreno-gonzalez, C. Santa-maria et al., Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease, Neurobiol. Aging, vol.27, pp.1658-1672, 2006.

A. Rozycka and M. Liguz-lecznar, The space where aging acts: focus on the GABAergic synapse, Aging Cell, vol.16, pp.634-643, 2017.

T. Saito, N. Iwata, S. Tsubuki, Y. Takaki, J. Takano et al., Somatostatin regulates brain amyloid ? peptide A?42 through modulation of proteolytic degradation, Nat. Med, vol.11, pp.434-439, 2005.

D. Saiz-sanchez, C. De-la-rosa-prieto, I. Ubeda-banon, and A. Martinez-marcos, Interneurons, tau and amyloid-? in the piriform cortex in Alzheimer's disease, Brain Struct. Funct, vol.220, 2011.

D. Saiz-sanchez, A. Flores-cuadrado, I. Ubeda-bañon, C. De-la-rosa-prieto, and A. Martinez-marcos, Interneurons in the human olfactory system in Alzheimer's disease, Exp. Neurol, vol.276, pp.13-21, 2016.

R. A. Sperling, P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.280-292, 2011.

E. M. Stanley, J. R. Fadel, and D. D. Mott, Interneuron loss reduces dendritic inhibition and GABA release in hippocampus of aged rats, Neurobiol. Aging, vol.33, 2012.

C. L. Sutphen, M. S. Jasielec, A. R. Shah, E. M. Macy, C. Xiong et al., Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age, JAMA Neurol, vol.72, pp.1029-1042, 2015.

C. A. Tamminga, N. L. Foster, P. Fedio, E. D. Bird, and T. N. Chase, Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism, Neurology, vol.37, pp.161-165, 1987.

L. Thurstone and T. Thurstone, Manuel d'application de la Batterie Factorielle P.M.A (Primary Mental Activities), 1964.

T. N. Tombaugh, Trail making test A and B: normative data stratified by age and education, Arch. Clin. Neuropsychol, vol.19, pp.39-47, 2004.

G. Tundo, C. Ciaccio, D. Sbardella, M. Boraso, B. Viviani et al., Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD, PLoS One, vol.7, p.34376, 2012.

J. W. Unger and W. Lange, NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease, Acta Neuropathol, vol.83, pp.636-646, 1992.

H. Vanderstichele, K. De-vreese, K. Blennow, N. Andreasen, C. Sindic et al., Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies, Clin. Chem. Lab. Med, vol.44, pp.1472-1480, 2006.

V. Villette, F. Poindessous-jazat, B. Bellessort, E. Roullot, Y. Peterschmitt et al., A new neuronal target for ?-amyloid peptide in the rat hippocampus, Neurobiol. Aging, vol.33, pp.1-1126, 1126.

V. Villette, F. Poindessous-jazat, A. Simon, C. Léna, E. Roullot et al., Decreased rhythmic GABAergic septal activity and memoryassociated theta oscillations after hippocampal amyloid-? pathology in the rat, J. Neurosci, vol.30, pp.10991-11003, 2010.

H. Wang, L. D. Muiznieks, P. Ghosh, D. Williams, M. Solarski et al., Somatostatin binds to the human amyloid ? peptide and favors the formation of distinct oligomers, Elife, vol.6, p.28401, 2017.

G. S. Watson, L. D. Baker, B. A. Cholerton, K. W. Rhoads, G. R. Merriam et al., Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease, J. Alzheimers Dis, vol.18, pp.595-602, 2009.

D. M. Wilcock, M. R. Lewis, W. E. Van-nostrand, J. Davis, M. L. Previti et al., Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2, J. Neurosci, vol.28, pp.1537-1545, 2008.

J. A. Yesavage, Geriatric depression scale, Psychopharmacol. Bull, vol.24, pp.709-711, 1988.

, Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

. Duron, . Vidal, . Grousselle, . Gabelle, . Lehmann et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, Copyright, 2018.